Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 1/20 | 0.50 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.50 |
| ▸ | MMP13 | P45452 | 2/20 | 0.47 |
| ▸ | LSS | P48449 | 1/20 | 0.47 |
| ▸ | MMP12 | P39900 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | RORC | P51449 | 2/20 | 0.45 |
| ▸ | LIPG | Q9Y5X9 | 3/20 | 0.45 |
| ▸ | LIPC | P11150 | 1/20 | 0.45 |
| ▸ | MMP2 | P08253 | 1/20 | 0.44 |
| ▸ | CCR1 | P32246 | 1/20 | 0.42 |
| ▸ | CCR3 | P51677 | 1/20 | 0.42 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.42 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4698133 | 1.00 | FPR2 (0.50) | FPR2PROKR1MMP13LSSMMP12 | |
| SCHEMBL4701316 | 1.00 | FPR2 (0.50) | FPR2PROKR1MMP13LSSMMP12 | |
| SCHEMBL4702501 | 0.87 | FPR2 (0.51) | FPR2PROKR1MMP13LSSMMP12 | |
| SCHEMBL4698150 | 0.87 | FPR2 (0.51) | FPR2PROKR1MMP13LSSMMP12 | |
| SCHEMBL4698148 | 0.87 | FPR2 (0.51) | FPR2PROKR1MMP13LSSMMP12 | |
| SCHEMBL26689993 | 0.76 | SOS1 (0.43) | FPR2PROKR1MMP13LSSMMP12 | |
| SCHEMBL10262288 | 0.74 | HTR2C (0.60) | FPR2PROKR1SMN1; SMN2MAPTLIPG | |
| SCHEMBL10079036 | 0.74 | HTR2C (0.60) | FPR2PROKR1SMN1; SMN2MAPTLIPG | |
| SCHEMBL10261788 | 0.74 | HTR2C (0.60) | FPR2PROKR1SMN1; SMN2MAPTLIPG | |
| SCHEMBL14040636 | 0.74 | MMP13 (0.40) | FPR2PROKR1MMP13LSSMMP12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1444202-B1 | NOVEL METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2008-10-15 | — | — | EP | disclosed |
| US-7132434-B2 | Metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2006-11-07 | — | — | US | disclosed |
| US-20050026990-A1 | Novel metalloproteinase ihibitors | ASTRAZENECA AB (SE) | 2005-02-03 | — | — | US | disclosed |
| EP-1444202-A1 | NOVEL METALLOPROTEINASE INHIBITORS | AstraZeneca AB (SE) | 2004-08-11 | — | — | EP | disclosed |
| WO-2003040098-A1 | NOVEL METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2003-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026990-A1 | Novel metalloproteinase ihibitors | MMP12, MMP1, MMP16 | FPR2 4081/4885PROKR1 2516/4885MMP13 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.